san 202791 has been researched along with diltiazem in 1 studies
Studies (san 202791) | Trials (san 202791) | Recent Studies (post-2010) (san 202791) | Studies (diltiazem) | Trials (diltiazem) | Recent Studies (post-2010) (diltiazem) |
---|---|---|---|---|---|
31 | 0 | 2 | 6,402 | 1,073 | 578 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bacon, KB; Camp, RD; Westwick, J | 1 |
1 other study(ies) available for san 202791 and diltiazem
Article | Year |
---|---|
Potent and specific inhibition of IL-8-, IL-1 alpha- and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists.
Topics: Calcium Channel Blockers; Chemotactic Factors; Chemotaxis, Leukocyte; Dihydropyridines; Diltiazem; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Interleukin-1; Interleukin-8; Interleukins; Kinetics; Lymphocytes; Nifedipine; Recombinant Proteins; Verapamil | 1989 |